Calista Therapeutics was founded in 2012 by peptide therapeutic pioneer and biotech entrepreneur, Andrew Mallon, building upon years of research and business experience in discovering and developing peptide drugs. Calista scientists are today developing these promising leads to create more effective and safe medicines for the treatment of cystic fibrosis, dry eye, radiation damage, neuroprotection and other indications. Our expertise in the pharmacology and development of peptide drugs that interact with key cellular disease targets.
Looking for a particular Calista Therapeutics, Inc. employee's phone or email?
The Calista Therapeutics, Inc. annual revenue was $3.8 million in 2026.
Calista Therapeutics, Inc. is based in Lincoln, Rhode Island.
The NAICS codes for Calista Therapeutics, Inc. are [32, 3254, 325].
The SIC codes for Calista Therapeutics, Inc. are [283, 28].